Cortical excitability distinguishes ALS from mimic disorders

Clinical Neurophysiology

Volumn 122, Issue 9, 2011, Pages 1860-1866

  Vucic, Steve ^a,b   Cheah, Benjamin C ^b,c   Yiannikas, Con ^d   Kiernan, Matthew C ^b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Amyotrophic lateral sclerosis; Cortical excitability; Diagnosis; Threshold tracking TMS

Indexed keywords

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CORTICAL EXCITABILITY; EVOKED MUSCLE RESPONSE; FEMALE; HUMAN; INHIBITION (PSYCHOLOGY); MAJOR CLINICAL STUDY; MALE; MOTOR NEURON DISEASE; NERVE EXCITABILITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SHORT INTERVAL INTRACORTICAL INHIBITION; TRANSCRANIAL MAGNETIC STIMULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; AMYOTROPHIC LATERAL SCLEROSIS; AREA UNDER CURVE; CEREBRAL CORTEX; DIAGNOSIS, DIFFERENTIAL; EVOKED POTENTIALS, MOTOR; FEMALE; HUMANS; MALE; MIDDLE AGED; ROC CURVE; SENSITIVITY AND SPECIFICITY; TRANSCRANIAL MAGNETIC STIMULATION; YOUNG ADULT;

EID: 79960891825     PISSN: 13882457     EISSN: 18728952     Source Type: Journal    
DOI: 10.1016/j.clinph.2010.12.062     Document Type: Article

References (45)

1. Aggarwal S., Cudkowicz M. ALS drug development: reflections from the past and a way forward. Neurotherapeutics 2008, 5:516-527.
2. Askanas V., Wojcik S., Engel W.K. Expression of Nogo-A in human muscle fibers is not specific for amyotrophic lateral sclerosis. Ann Neurol 2007, 62:676-677.
3. Bensimon G., Lacomblez L., Delumeau J.C., Bejuit R., Truffinet P., Meininger V. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol 2002, 249:609-615.
4. Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/riluzole study group. N Engl J Med 1994, 330:585-591.
5. Boekestein W.A., Kleine B.U., Hageman G., et al. Sensitivity and specificity of the 'Awaji' electrodiagnostic criteria for amyotrophic lateral sclerosis: retrospective comparison of the Awaji and revised El Escorial criteria for ALS. Amyotroph Lateral Scler 2010, 11:497-501.
6. Boillee S., Vande Velde C., Cleveland D.W. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52:39-59.
7. Brooks B.R., Miller R.G., Swash M., Munsat T.L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler & Other Motor Neuron Disord 2000, 1:293-299.
8. Carvalho M.D., Swash M. Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler 2009, 10:53-57.
9. Cedarbaum J.M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci 1999, 169:13-21.
10. Chen R., Cros D., Curra A., Di Lazzaro V., Lefaucheur J.P., Magistris M.R., et al. The clinical diagnostic utility of transcranial magnetic stimulation: report of an IFCN committee. Clin Neurophysiol 2008, 119:504-532.
11. Chen R., Wassermann E.M., Canos M., Hallett M. Impaired inhibition in writer's cramp during voluntary muscle activation. Neurology 1997, 49:1054-1059.
12. Chio A. ISIS survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. J Neurol 1999, 246(Suppl. 3):III1-III5.
13. de Carvalho M., Dengler R., Eisen A., England J.D., Kaji R., Kimura J., et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008, 119:497-503.
14. de Carvalho M., Swash M. Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve 2000, 23:344-352.
15. Douglass C.P., Kandler R.H., Shaw P.J., McDermott C.J. An evaluation of neurophysiological criteria used in the diagnosis of motor neuron disease. J Neurol Neurosurg Psychiatry 2010, 81:646-649.
16. Gurney M.E., Cutting F.B., Zhai P., Doble A., Taylor C.P., Andrus P.K., et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996, 39:147-157.
17. Gurney M.E., Fleck T.J., Himes C.S., Hall E.D. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 1998, 50:62-66.
18. Hanajima R., Ugawa Y., Terao Y., Sakai K., Furubayashi T., Machii K., et al. Cortico-cortical inhibition of the motor cortical area projecting to sternocleidomastoid muscle in normals and patients with spasmodic torticollis or essential tremor. Electroencephalogr Clin Neurophysiol 1998, 109:391-396.
19. Jokic N., Gonzalez de Aguilar J.L., Pradat P.F., Dupuis L., Echaniz-Laguna A., Muller A., et al. Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann Neurol 2005, 57:553-556.
20. Kiernan M. Motor neuron disease: a Pandora's box. Med J Aust 2003, 178:311-312.
21. Kiernan M.C. Hyperexcitability, persistent Na+ conductances and neurodegeneration in amyotrophic lateral sclerosis. Exp Neurol 2009, 218:1-4.
22. Lacomblez L., Bensimon G., Leigh P.N., Guillet P., Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/riluzole study group II. Lancet 1996, 347:1425-1431.
23. Lehky T.J., Chen C.J., di Prospero N.A., Rhodes L.E., Fischbeck K., Floeter M.K. Standard and modified statistical MUNE evaluations in spinal-bulbar muscular atrophy. Muscle Nerve 2009, 40:809-814.
24. Medical Research Council. Aid to the examination of the peripheral nervous system. London: Her Majesty's Stationary Office; 1976.
25. Mills K.R., Murray N.M. Electrical stimulation over the human vertebral column: which neural elements are excited?. Electroencephalogr Clin Neurophysiol 1986, 63:582-589.
26. Rosenkranz K., Williamon A., Butler K., Cordivari C., Lees A.J., Rothwell J.C. Pathophysiological differences between musician's dystonia and writer's cramp. Brain 2005, 128:918-931.
27. Rossini P.M., Rossi S. Transcranial magnetic stimulation: diagnostic, therapeutic, and research potential. Neurology 2007, 68:484-488.
28. Rothstein J.D., Kuncl R.W. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem 1995, 65:643-651.
29. Traynor B.J., Codd M.B., Corr B., Forde C., Frost E., Hardiman O.M. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch Neurol 2000, 57:1171-1176.
30. Trotti D., Rolfs A., Danbolt N.C., Brown R.H., Hediger M.A. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci 1999, 2:848.
31. Turner M.R., Kiernan M.C., Leigh P.N., Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 2009, 8:94-109.
32. Vucic S., Burke D., Kiernan M.C. Diagnosis of motor neuron disease. The motor neuron disease handbook 2007, 89-115. Australasian Medical Publishing Company Limited, Sydney. M.C. Kiernan (Ed.).
33. Vucic S., Cheah B.C., Krishnan A.V., Burke D., Kiernan M.C. The effects of alterations in conditioning stimulus intensity on short interval intracortical inhibition. Brain Res 2009, 1273:39-47.
34. Vucic S., Howells J., Trevillion L., Kiernan M.C. Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve 2006, 33:477-486.
35. Vucic S., Kiernan M. Pathophysiology of degeneration in familial amyotrophic lateral sclerosis. Curr Mol Med 2009, 9:255-272.
36. Vucic S., Kiernan M.C. Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2007, 78:849-852.
37. Vucic S., Kiernan M.C. Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin Neurophysiol 2008, 119:1088-1096.
38. Vucic S., Kiernan M.C. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain 2006, 129:2436-2446.
39. Vucic S., Kiernan M.C. Pathophysiological insights into motor axonal function in Kennedy's disease. Neurology 2007, 69:1828-1835.
40. Vucic S., Nicholson G.A., Kiernan M.C. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 2008, 131:1540-1550.
41. Vucic S., Tian D., Chong P.S., Cudkowicz M.E., Hedley-Whyte E.T., Cros D. Facial onset sensory and motor neuronopathy (FOSMN syndrome): a novel syndrome in neurology. Brain 2006, 129:3384-3390.
42. Winhammar J.M., Rowe D.B., Henderson R.D., Kiernan M.C. Assessment of disease progression in motor neuron disease. Lancet Neurol 2005, 4:229-238.
43. Zanette G., Manganotti P., Fiaschi A., Tamburin S. Modulation of motor cortex excitability after upper limb immobilization. Clin Neurophysiol 2004, 115:1264-1275.
44. Ziemann U., Chen R., Cohen L.G., Hallett M. Dextromethorphan decreases the excitability of the human motor cortex. Neurology 1998, 51:1320-1324.
45. Ziemann U., Winter M., Reimers C.D., Reimers K., Tergau F., Paulus W. Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis. Evidence from paired transcranial magnetic stimulation. Neurology 1997, 49:1292-1298.